Forecasting the Future of Urology Practice: A Comprehensive Review of the Recommendations by International and European Associations on Priority Procedures During the COVID-19 Pandemic.
Ambulatory Care
/ trends
Betacoronavirus
COVID-19
Coronavirus Infections
/ epidemiology
Europe
/ epidemiology
Forecasting
Hospitalization
/ trends
Humans
Minimally Invasive Surgical Procedures
/ trends
Pandemics
Pneumonia, Viral
/ epidemiology
Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical
Telemedicine
/ trends
Urologic Diseases
/ diagnosis
Urologic Neoplasms
/ diagnosis
Urologic Surgical Procedures
/ trends
Urology
/ organization & administration
Association
COVID-19
Coronavirus
Priority
Society
Urology
Journal
European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661
Informations de publication
Date de publication:
15 Sep 2020
15 Sep 2020
Historique:
received:
04
05
2020
accepted:
24
05
2020
pubmed:
20
6
2020
medline:
21
8
2020
entrez:
20
6
2020
Statut:
ppublish
Résumé
The unprecedented health care scenario caused by the coronavirus disease 2019 (COVID-19) pandemic has revolutionized urology practice worldwide. To review the recommendations by the international and European national urological associations/societies (UASs) on prioritization strategies for both oncological and nononcological procedures released during the current emergency scenario. Each UAS official website was searched between April 8 and 18, 2020, to retrieve any document, publication, or position paper on prioritization strategies regarding both diagnostic and therapeutic urological procedures, and any recommendations on the use of telemedicine and minimally invasive surgery. We collected detailed information on all urological procedures, stratified by disease, priority (higher vs lower), and patient setting (outpatient vs inpatient). Then, we critically discussed the implications of such recommendations for urology practice in both the forthcoming "adaptive" and the future "chronic" phase of the COVID-19 pandemic. Overall, we analyzed the recommendations from 13 UASs, of which four were international (American Urological Association, Confederation Americana de Urologia, European Association of Urology, and Urological Society of Australia and New Zealand) and nine national (from Belgium, France, Germany, Italy, Poland, Portugal, The Netherlands, and the UK). In the outpatient setting, the procedures that are likely to impact the future burden of urologists' workload most are prostate biopsies and elective procedures for benign conditions. In the inpatient setting, the most relevant contributors to this burden are represented by elective surgeries for lower-risk prostate and renal cancers, nonobstructing stone disease, and benign prostatic hyperplasia. Finally, some UASs recommended special precautions to perform minimally invasive surgery, while others outlined the potential role of telemedicine to optimize resources in the current and future scenarios. The expected changes will put significant strain on urological units worldwide regarding the overall workload of urologists, internal logistics, inflow of surgical patients, and waiting lists. In light of these predictions, urologists should strive to leverage this emergency period to reshape their role in the future. Overall, there was a large consensus among different urological associations/societies regarding the prioritization of most urological procedures, including those in the outpatient setting, urological emergencies, and many inpatient surgeries for both oncological and nononcological conditions. On the contrary, some differences were found regarding specific cancer surgeries (ie, radical cystectomy for higher-risk bladder cancer and nephrectomy for larger organ-confined renal masses), potentially due to different prioritization criteria and/or health care contexts. In the future, the outpatient procedures that are likely to impact the burden of urologists' workload most are prostate biopsies and elective procedures for benign conditions. In the inpatient setting, the most relevant contributors to this burden are represented by elective surgeries for lower-risk prostate and renal cancers, nonobstructing stone disease, and benign prostatic hyperplasia.
Identifiants
pubmed: 32553544
pii: S2405-4569(20)30142-5
doi: 10.1016/j.euf.2020.05.007
pmc: PMC7261455
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1032-1048Informations de copyright
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Références
Eur Urol. 2020 Jun;77(6):675-682
pubmed: 31918957
Adv Radiat Oncol. 2020 Apr 01;5(4):659-665
pubmed: 32292839
Eur Urol Oncol. 2018 Aug;1(3):177-187
pubmed: 31102618
BJU Int. 2020 Jun;125(6):E3-E4
pubmed: 32232915
Minerva Urol Nefrol. 2019 Aug;71(4):421-425
pubmed: 30421592
Minerva Urol Nefrol. 2020 Jun;72(3):376-383
pubmed: 32225135
Curr Opin Nephrol Hypertens. 2020 Mar;29(2):237-242
pubmed: 31972597
Minerva Urol Nefrol. 2019 Feb;71(1):17-30
pubmed: 30421598
Eur Urol Focus. 2019 May;5(3):351-356
pubmed: 31204291
Eur Urol Oncol. 2020 Apr;3(2):239-249
pubmed: 31668714
Minerva Urol Nefrol. 2020 Apr;72(2):173-186
pubmed: 30957473
Eur Urol. 2020 Jul;78(1):122-124
pubmed: 32331707
Eur Urol. 2018 Jul;74(1):10-14
pubmed: 29653885
Ann Surg. 2020 Jul;272(1):e5-e6
pubmed: 32221118
Eur Urol. 2020 Jun;77(6):663-666
pubmed: 32279903
J Urol. 2020 Jul;204(1):9-10
pubmed: 32249681
Minerva Urol Nefrol. 2019 Dec;71(6):644-650
pubmed: 31166100
Minerva Urol Nefrol. 2020 Feb;72(1):58-65
pubmed: 31086135
Eur Urol. 2020 Jul;78(1):16-20
pubmed: 32362498
Minerva Urol Nefrol. 2020 Aug;72(4):505-509
pubmed: 32253371
Sex Med Rev. 2019 Oct;7(4):559-564
pubmed: 31351916
Eur Urol. 2020 Aug;78(2):131-133
pubmed: 32303384
Curr Opin Oncol. 2020 Jan;32(1):27-34
pubmed: 31644473
Eur Urol. 2020 Jul;78(1):29-42
pubmed: 32414626
Minerva Urol Nefrol. 2020 Feb;72(1):13-21
pubmed: 31241273
J Urol. 2020 Jul;204(1):11-13
pubmed: 32249715
Minerva Urol Nefrol. 2019 Feb;71(1):38-46
pubmed: 30547906
Minerva Urol Nefrol. 2020 Jun;72(3):369-375
pubmed: 32202401
Eur Urol. 2020 Jul;78(1):e12-e13
pubmed: 32336644
Minerva Urol Nefrol. 2019 Jun;71(3):191-200
pubmed: 30654603
Eur Urol. 2020 Jun;77(6):748-754
pubmed: 32317180
Eur Urol. 2020 Jul;78(1):11-15
pubmed: 32307215
J Urol. 2020 Jul;204(1):14-16
pubmed: 32249678
Eur Urol. 2020 Jul;78(1):21-28
pubmed: 32376137